Lakeview Capital Partners LLC maintained its position in Boston Scientific Corporation (NYSE:BSX) during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 10,561 shares of the medical equipment provider’s stock at the end of the first quarter. Lakeview Capital Partners LLC’s holdings in Boston Scientific Corporation were worth $263,000 at the end of the most recent reporting period.
Several other institutional investors have also recently bought and sold shares of BSX. Quadrant Capital Group LLC increased its position in Boston Scientific Corporation by 10.3% in the first quarter. Quadrant Capital Group LLC now owns 5,201 shares of the medical equipment provider’s stock valued at $122,000 after buying an additional 487 shares during the last quarter. Bronfman E.L. Rothschild L.P. increased its stake in shares of Boston Scientific Corporation by 7.2% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 5,041 shares of the medical equipment provider’s stock worth $125,000 after buying an additional 338 shares in the last quarter. Commerce Bank bought a new stake in shares of Boston Scientific Corporation during the first quarter worth about $207,000. Los Angeles Capital Management & Equity Research Inc. bought a new stake in shares of Boston Scientific Corporation during the first quarter worth about $215,000. Finally, Breton Hill Capital Ltd. acquired a new stake in Boston Scientific Corporation during the first quarter valued at $224,000. 92.04% of the stock is currently owned by institutional investors.
Shares of Boston Scientific Corporation (NYSE BSX) traded down 0.14% during mid-day trading on Tuesday, hitting $28.21. 1,726,782 shares of the stock traded hands. The firm has a 50 day moving average of $27.03 and a 200 day moving average of $24.66. The stock has a market cap of $38.63 billion, a price-to-earnings ratio of 90.42 and a beta of 1.05. Boston Scientific Corporation has a 12 month low of $19.67 and a 12 month high of $28.51.
Boston Scientific Corporation (NYSE:BSX) last posted its quarterly earnings data on Thursday, April 27th. The medical equipment provider reported $0.29 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.30 by $0.01. Boston Scientific Corporation had a return on equity of 23.45% and a net margin of 5.07%. The company had revenue of $2.16 billion for the quarter, compared to analyst estimates of $2.08 billion. During the same quarter in the prior year, the company posted $0.28 earnings per share. The business’s revenue was up 10.0% on a year-over-year basis. On average, equities analysts expect that Boston Scientific Corporation will post $1.25 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This article was first posted by Stock Observer and is the property of of Stock Observer. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.thestockobserver.com/2017/06/20/boston-scientific-corporation-bsx-stake-held-by-lakeview-capital-partners-llc-updated.html.
A number of research analysts have recently commented on BSX shares. Needham & Company LLC reiterated a “buy” rating and issued a $29.00 price target on shares of Boston Scientific Corporation in a research note on Thursday, February 23rd. Zacks Investment Research lowered Boston Scientific Corporation from a “hold” rating to a “sell” rating in a research report on Wednesday, April 5th. Northland Securities reiterated a “positive” rating on shares of Boston Scientific Corporation in a report on Thursday, February 23rd. TheStreet downgraded Boston Scientific Corporation from a “b” rating to a “c+” rating in a report on Thursday, March 16th. Finally, Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Boston Scientific Corporation in a research note on Thursday, February 23rd. Six research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $28.41.
In other news, EVP Michael P. Phalen sold 79,045 shares of the stock in a transaction dated Wednesday, March 29th. The shares were sold at an average price of $24.55, for a total transaction of $1,940,554.75. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Timothy A. Pratt sold 10,000 shares of the stock in a transaction dated Monday, April 3rd. The stock was sold at an average price of $24.87, for a total transaction of $248,700.00. Following the sale, the executive vice president now directly owns 235,846 shares in the company, valued at approximately $5,865,490.02. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 217,916 shares of company stock valued at $5,606,540. 0.74% of the stock is currently owned by insiders.
About Boston Scientific Corporation
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.